<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218917</url>
  </required_header>
  <id_info>
    <org_study_id>INS1007-201</org_study_id>
    <secondary_id>2017-002533-32</secondary_id>
    <nct_id>NCT03218917</nct_id>
  </id_info>
  <brief_title>Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety &amp; Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a
      24-week treatment period in patients with non-cystic fibrosis bronchiectasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter,
      multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics
      (PK) of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis
      bronchiectasis (NCFBE).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first pulmonary exacerbation</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Exacerbation is defined by signs and symptoms plus intervention with systemic antibiotics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of pulmonary exacerbations</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Number of events per person-time over 24-weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Respiratory Symptoms Domain Score of the Quality of Life (QOL) Bronchiectasis questionnaire</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Change from Baseline symptom score at 24-weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Screening in post-bronchodilator forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Change from Screening in FEV1 at 24-weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of active neutrophil elastase (NE) in sputum from pre-treatment to on treatment</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Change in concentration of active NE in sputum from pretreatment defined as as the average of Screening and Day 1 concentrations) to on-treatment (defined as the average of Week 12 and Week 24 concentrations).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in QOL-B scores (excluding Respiratory Symptoms Domain)</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Change from Baseline in score of QOL-B domains (excluding respiratory symptoms domain) at 24-weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in Leicester Cough Questionnaire (LCQ) score</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Change from Baseline in LCQ score at 24-weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) score</measure>
    <time_frame>24-week treatment period</time_frame>
    <description>Change from Baseline in SGRQ total score at 24- weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Screening of forced vital capacity (FVC)</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Change from Screening of FVC at Weeks 12 and 24.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Screening of peak expiratory flow rate (PEFR)</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Change from Screening of PEFR at Weeks 12 and 24.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Screening of forced exploratory flow 25% to 75% (FEF25-75)</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Change from Screening in FEF25-75 at Weeks 12 and 24.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Non-Cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>INS1007 10 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INS1007 25 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once per day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS1007 10 mg oral tablet</intervention_name>
    <description>Administered once per day for 24 weeks</description>
    <arm_group_label>INS1007 10 mg Oral Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS1007 25 mg oral tablet</intervention_name>
    <description>Administered once per day for 24 weeks</description>
    <arm_group_label>INS1007 25 mg Oral Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Administered once per day for 24 weeks</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or
             recurrent respiratory infections)

          2. Are current sputum producers with a history of chronic expectoration and able to
             provide a sputum sample during Screening

          3. Have at least 2 documented pulmonary exacerbations in the past 12 months before
             Screening

        Exclusion Criteria:

          1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma

          2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common
             variable immunodeficiency, or alpha1-antitrypsin deficiency

          3. Are current smokers

          4. Are currently being treated for a nontuberculous mycobacterial lung infection,
             allergic bronchopulmonary aspergillosis, or tuberculosis

          5. Have any acute infections, (including respiratory infections)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tomoko Shibata</last_name>
    <phone>+1.908.947.2821</phone>
    <email>tomoko.shibata@insmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathryn Lunga</last_name>
    <phone>+1.908.947.4304</phone>
    <email>kathryn.lunga@insmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NewportNativeMD</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Woosley</last_name>
      <phone>949-791-8599</phone>
      <email>tiffany@newportnativemd.com</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Frisby</last_name>
      <phone>949-791-8599</phone>
      <email>leslie@newportnativemd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P aeruginosa</keyword>
  <keyword>bronchiectasis</keyword>
  <keyword>active neutrophil elastase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

